In a release, the company said it adopted a shareholder rights plan in response to an offer from All Blue Falcons FZE to buy the company. (The Logic)
In a release, the company said it adopted a shareholder rights plan in response to an offer from All Blue Falcons FZE to buy the company. (The Logic)
In a release, the company said it adopted a shareholder rights plan in response to an offer from All Blue Falcons FZE to buy the company. (The Logic)
Talking point: “The rights plan will reduce the likelihood that any entity, person or group gains control of Zymeworks through open market accumulation without paying all shareholders an appropriate control premium,” the company wrote. Last month, Zymeworks rejected an unsolicited proposal from All Blue to acquire the company for $10.50 per share, saying it undervalued the company. The Dubai-based investment fund owned 6.9 per cent of the company as of May 26, SEC disclosures show. Zymeworks’s stock fell this morning after disclosing the poison pill and closed about four per cent lower to $6.11. Its shares traded above $30 for most of 2021 before dropping significantly beginning last August.
Loading...
You have shared 5 articles this month and reached the maximum amount of shares available.
CloseIf you would like to purchase a sharing license please contact The Logic support at [email protected].
CloseYou have gifted 0 article(s) this month and have 5 remaining.
Recipients will be able to read the full text of the article after submitting their email address. They will not have access to other articles or subscriber benefits.
Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.
See the bigger picture with reporters and industry experts in subscriber-exclusive events.
Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our journalists and special guests.